Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

ConditionHematologic Malignancies

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorAsmaa Hassan mohamed Abdel Mawjoud

About this trial

CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

Eligibility criteria

Qualifiers

Patients with hematologic malignancies.

Newly diagnosed

Disqualifiers

Patients with hematologic disorders other than hematologic malignancies.

Trial design

Treatments tested in this trial

CD56

Treatment groups

38 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Asmaa Hassan mohamed Abdel Mawjoud

Lead sponsor

Assiut University

Sponsor institution

Source ClinicalTrials.gov